 FOSTER CITY, Calif.-- BUSINESS WIRE --Geron Corporation Nasdaq: GERN today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Companys first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes MDS on January 4, 2023, at 8:00 a.m. ET. 